About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: RIGL
- CUSIP: 76655960
- Previous Close: $2.32
- 50 Day Moving Average: $2.30
- 200 Day Moving Average: $2.81
- 52-Week Range: $1.88 - $4.38
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.48
- P/E Growth: -0.05
- Market Cap: $227.56M
- Outstanding Shares: 98,937,000
- Beta: 1.24
- Net Margins: -255.84%
- Return on Equity: -86.54%
- Return on Assets: -61.98%
Companies Related to Rigel Pharmaceuticals:
- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 4.19%
- Quick Ratio: 4.19%
What is Rigel Pharmaceuticals' stock symbol?
Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?
6 equities research analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $6.20 in the next twelve months.
When will Rigel Pharmaceuticals announce their earnings?
Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Rigel Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
- BMO Capital Markets analysts commented, "We believe follow-up data from the fostamatinib Phase III program further supports Rigel's decision to move forward with the NDA filing, and our belief that the addressable population will be greater than the 18% stable response rate seen in the pivotal studies. We believe reaching an FDA Adcom would be a positive event, as we believe a panel of clinicians would likely favor approval." (1/30/2017)
Jefferies Group LLC analysts commented, "Despite mixed fosta Ph3 data in ITP, RIGL is on track to file an IND in 1Q17 based on its discussion with its regulatory consultant & no FDA objection to date. Key catalysts include: (1) FDA decision on acceptance of fosta NDA by ~May 2017, & (2) AdComm outcome (if NDA accepted) in ~Sept./Oct." (1/11/2017)
According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (12/31/2016)
Piper Jaffray Companies analysts commented, "Celsion announced that the independent Data Safety Monitoring Board (DSMB) has reviewed the data from the first three cohorts (N=9) of patients treated with GEN-1 (DNA-based IL-12) in the phase Ib Ovation study (ovarian cancer) and recommended that the study proceed to treating the fourth and final cohort." (9/15/2016)
Who owns Rigel Pharmaceuticals stock?
Rigel Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Palo Alto Investors LLC (4.22%), Patrick Lee, MD (4.22%), State Street Corp (1.73%), Dimensional Fund Advisors LP (1.20%) and J. Goldman & Co LP (0.79%).
Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?
Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Dimensional Fund Advisors LP, Two Sigma Investments LP, Marshall Wace LLP, First Republic Investment Management Inc. and Metropolitan Life Insurance Co. NY.
Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?
Rigel Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Paulson & CO. Inc., Russell Investments Group Ltd., State Street Corp and J. Goldman & Co LP.
How do I buy Rigel Pharmaceuticals stock?
Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Rigel Pharmaceuticals stock cost?
One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.30.